Despite the ever-expanding clinical evaluation of molecularly targeted anticancer agents, little progress has been made in preventing metastases, the leading cause of death in patients with cancer. Although there has been some success in controlling tumor growth, this has not translated in achieving favorable overall survival outcomes. Patricia Steeg, PhD, from the National Cancer Institute (NCI), suggests that the FDA could spur initiation of trials with drugs designed to prevent metastases by considering a delay of cancer spread as a satisfactory endpoint for approval
Source: “Perspective: The right trials.” Steeg PS. Nature. 2012 May 30;485(7400):S58-9.
Free paper available at: